Can an ultra-long-acting factor VIII simplify surgery for hemophilia a patients?
NCT ID NCT07723560
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This study collects real-world data on how hemophilia A patients are managed during and after surgery when using efanesoctocog alfa (Altuvoct), a long-acting clotting factor. Researchers will track how much of the drug is needed, how often it is given, and how long patients stay in the hospital. The goal is to compare these results with those from an older clotting factor and help standardize surgical care across centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- efanesoctocog alfa (Altuvoct), a long-acting factor VIII replacement therapy
- What this could lead to
- If successful, this study could help standardize surgical protocols for hemophilia A patients using ultra-long-acting factor VIII, potentially improving outcomes and reducing variability across hospitals.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may vary widely due to differences in surgical procedures and patient characteristics.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FACTOR VIII are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Unité d'Hémostase Clinique Centre Régional de Traitement des Hémophiles Centre de Référence de Maladies Hémorragiques Hôpital Cardiologique Louis Pradel
RECRUITINGBron, 69500, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Patient voices take center stage in haemophilia a treatment decisions
- Japanese study tracks Esperoct's Real-World safety over two years
- Japanese hemophilia patients monitored on alhemo in new safety study
- New hope for haemophilia a patients: immune tolerance induction may eliminate clotting factor blockers
- Hemophilia a treatment comparison study canceled before starting
- New hope for kids with hemophilia: can SCT800 stop bleeds before they start?